Vir Biotechnology, Inc.於2016年4月7日根據特拉華州法律註冊成立。作為一家臨床階段的生物製藥公司，VIR致力於增強免疫系統，以開發針對嚴重傳染病和癌症的創新療法。該公司的方法側重於解決這些威脅逃避免疫防禦的複雜機制。Vir的臨床開發管道包括針對德爾塔型肝炎病毒和各種實體瘤的療法，正在進行的臨床項目和試驗显示出新的護理標準的前景。該公司利用其專有技術平台DAISY和PRO-XTEN來優化抗體開發。憑藉在免疫學、傳染病和腫瘤學方面經驗豐富的領導團隊，VIR致力於通過其變革性療法改變生活。
董事
名稱
職位
Marianne De Backer
President, Chief Executive Officer and Director
Elliott Sigal
Independent Director
Janet Napolitano
Independent Director
Jeffrey S. Hatfield
Board Chair
Norbert Bischofberger
Independent Director
Ramy Farid
Independent Director
Robert More
Independent Director
股東
名稱
職位
Marianne De Backer
President, Chief Executive Officer and Director
Jason O byrne
Executive Vice President and Chief Financial Officer
Mark Eisner
Executive Vice President and Chief Medical Officer
Vanina de Verneuil
Executive Vice President, General Counsel and Corporate Secretary